Evicenter
Opdivo (nivolumab) in Metastatic non-small cell lung cancer
Manufacturer
Bristol-Myers Squibb Company
Prescribing information
Opdivo (opens in a new tab)
Questions
60
Last updated

All questions

Guidelines: Opdivo (nivolumab) in metastatic non-small cell lung cancer

3 questions · 3 sources

Guidelines

Does NCCN recommend Opdivo plus Yervoy for first-line metastatic NSCLC?

Applies to First-line metastatic NSCLC in adults whose tumors express PD-L1 (≥1%), with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (Checkmate 227)

Does NCCN recommend Opdivo plus Yervoy and chemotherapy for metastatic NSCLC?

Applies to First-line metastatic or recurrent NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy (Checkmate 9LA)

Does NCCN support Opdivo Qvantig for previously treated metastatic NSCLC?

Applies to Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy